Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast
Interventions: DRUG: Pembrolizumab|DRUG: nab-paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Institut fuer Frauengesundheit
Collaborators: Merck Sharp & Dohme LLC|Celgene Corporation